Natera Inc (NTRA : NASDAQ)
Common Stock
$395.56
USD
-5.09 (-1.27%)
Last updated: 2026-10-07
Follow NTRA
NTRA
Natera Inc
WealthAwesomePerformance
1 Day
-1.27%
1 Week
-4.29%
1 Month
+20.53%
YTD
+72.85%
Key Statistics
Market Cap
$57.75B
52W High
$437.41
52W Low
$167.99
P/E Ratio
-
50 Day MA
$334.34
200 Day MA
$250.04
Beta
1.50
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/7/2026 | $393.02 | $401.09 | $383.45 | $395.56 | $395.56 | 2,816,087 |
| 10/6/2026 | $429.01 | $437.41 | $394.77 | $400.65 | $400.65 | 2,496,351 |
| 10/5/2026 | $410.32 | $427.18 | $405.24 | $425.64 | $425.64 | 2,021,831 |
| 10/2/2026 | $409.40 | $413.36 | $401.00 | $410.35 | $410.35 | 1,871,300 |
| 10/1/2026 | $413.31 | $423.43 | $407.37 | $408.47 | $408.47 | 1,863,700 |
| 9/30/2026 | $416.02 | $427.47 | $413.29 | $413.31 | $413.31 | 1,845,100 |
| 9/29/2026 | $413.69 | $421.64 | $409.25 | $414.52 | $414.52 | 2,057,900 |
| 9/28/2026 | $409.02 | $417.38 | $406.30 | $411.77 | $411.77 | 1,644,300 |
| 9/25/2026 | $410.00 | $415.75 | $407.48 | $412.56 | $412.56 | 1,612,400 |
| 9/24/2026 | $390.52 | $412.93 | $388.46 | $408.79 | $408.79 | 1,963,000 |
Analyst Price Targets
Based on analyst covering NTRA · as of Oct 8, 2026
Wall Street analysts forecast NTRA stock price to fall 4.6% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
US$377.43
-4.6% Upside
Previously US$366.07 on Oct 7, 2026
Current Price
US$395.56
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on NTRA's historical volatility
30-Day Vol
39.6%
Annualized
90-Day Vol
51.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$472.90
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$419.82 | US$366.25 – US$481.22 |
| 60 trading days | US$445.57 | US$367.35 – US$540.45 |
| 90 trading days | US$472.90 | US$373.32 – US$599.03 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Natera Inc
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in Januar
Financials
- Revenue (TTM)
- $2.71B
- EBITDA
- $-224.42M
- Profit Margin
- -7.11%
- ROE (TTM)
- -12.54%
- EPS (Diluted)
- -1.35
- Book Value
- 12.68
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About NTRA.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| GLE | Global Engine Group Holding Limited Ordinary Shares | $4.00 | +877.02% |
| SXTC | China SXT Pharmaceuticals Inc | $2.83 | +126.40% |
| PFAI | Pinnacle Food Group Limited Class A Common Shares | $5.07 | +116.67% |
| CHARR | Charlton Aria Acquisition Corporation Rights | $0.18 | +80.00% |
| SBFM | Sunshine Biopharma Inc | $0.70 | +75.92% |
| BIYA | Baiya International Group Inc. Ordinary Shares | $2.30 | +68.50% |
| FEED | ENvue Medical Inc. | $0.43 | +50.84% |
| QETAR | Quetta Acquisition Corporation Right | $0.72 | +47.94% |
NTRA.US news timeline
1 article covering NTRA.US, most recent first
Latest